1. Home
  2. KRYS vs BTG Comparison

KRYS vs BTG Comparison

Compare KRYS & BTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • BTG
  • Stock Information
  • Founded
  • KRYS 2015
  • BTG 2006
  • Country
  • KRYS United States
  • BTG Canada
  • Employees
  • KRYS N/A
  • BTG N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • BTG Precious Metals
  • Sector
  • KRYS Health Care
  • BTG Basic Materials
  • Exchange
  • KRYS Nasdaq
  • BTG Nasdaq
  • Market Cap
  • KRYS 5.1B
  • BTG 4.2B
  • IPO Year
  • KRYS 2017
  • BTG N/A
  • Fundamental
  • Price
  • KRYS $170.21
  • BTG $2.72
  • Analyst Decision
  • KRYS Strong Buy
  • BTG Buy
  • Analyst Count
  • KRYS 8
  • BTG 3
  • Target Price
  • KRYS $199.43
  • BTG $4.12
  • AVG Volume (30 Days)
  • KRYS 236.9K
  • BTG 14.1M
  • Earning Date
  • KRYS 11-04-2024
  • BTG 11-06-2024
  • Dividend Yield
  • KRYS N/A
  • BTG 5.93%
  • EPS Growth
  • KRYS N/A
  • BTG N/A
  • EPS
  • KRYS 1.77
  • BTG N/A
  • Revenue
  • KRYS $241,519,000.00
  • BTG $1,914,216,000.00
  • Revenue This Year
  • KRYS $485.65
  • BTG N/A
  • Revenue Next Year
  • KRYS $58.64
  • BTG $34.69
  • P/E Ratio
  • KRYS $100.04
  • BTG N/A
  • Revenue Growth
  • KRYS 2722.80
  • BTG N/A
  • 52 Week Low
  • KRYS $96.73
  • BTG $2.34
  • 52 Week High
  • KRYS $219.34
  • BTG $3.50
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 42.62
  • BTG 28.01
  • Support Level
  • KRYS $182.26
  • BTG $2.66
  • Resistance Level
  • KRYS $207.84
  • BTG $3.44
  • Average True Range (ATR)
  • KRYS 8.55
  • BTG 0.11
  • MACD
  • KRYS -0.10
  • BTG -0.07
  • Stochastic Oscillator
  • KRYS 20.00
  • BTG 8.33

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About BTG B2Gold Corp Common shares (Canada)

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other significant assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into a global market. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

Share on Social Networks: